What Is CJD?
Creutzfeldt-Jakob disease (CJD) is a rare, degenerative brain disease. There are various forms of the disease, but the iatrogenic strain was first identified in 1985 amongst recipients of cadaveric human growth hormone (HGH).
What Is 'Human Growth Hormone'?
HGH was a product made from human pituitary glands processed in the UK by the Medical Research Council and given by injection to 1900 children between 1971 and 1985. Similar programmes ran in France, Australia and the United States.
From 1971-1984, a treatment programme was took place at Great Ormond Street Hospital to treat children who was growth velocity was abnormally low.
Children treated in the programme received allocations of growth hormone from batches processed by the MRC; these injections were administered three times a week (often by the patient’s family) for a number of years until improved growth velocity was achieved.
In 1985, cases of CJD were diagnosed after the deaths of patients in the UK and the USA and were attributed to deceased pituitary glands processed by the MRC. The programme was stopped and a year later, a programme of treatment with genetically engineered HGH replaced the cadaveric treatment.
Between 1991 and 1999 a series of Trials took place which established the liability of the Department of Health to compensate patients diagnosed with iatrogenic CJD who had been wholly or predominantly treated after 1 July 1977.
A group of ‘worried well’ claimants also recovered significant damages since those Trials a number of claimants who have developed iatrogenic CJD have been able to rely on these decisions to make successful claims for compensation.
How You Can Claim
If a member of your family suffered from iatrogenic Creutzfeldt-Jakob disease as a result of HGH treatment, please contact us and our expert solicitors will do their best to help.
Simply complete the form below and one of our experts will get back to you.